Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor replacement therapy has been the standard of care in hemophilia, although there are limitations to this approach. More recently, the approval of novel gene therapies has presented a promising option for patients with both hemophilia A and B.
In this podcast, you will hear from Michiel Coppens, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, and Johannes Oldenburg, MD, University Clinic Bonn, Bonn, Germany, who discuss the current standard of care in hemophilia and share some insights into the value of gene therapies.
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
The current status of CAR-T therapy in CLL and challenges in this space
Managing and treating GvHD and other post-transplant complications
The role of MRD in multiple myeloma
Novel immune therapies in MDS and challenges in this space
NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies
MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy
T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks
The importance of CD47 in MDS and other targets of interest
CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy
Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
iwNHL Session V: Novel therapies in NHL - the role of ADCs
iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML
The importance of genomic testing in CLL and its role in clinical decision-making
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies
iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.